PLOS PATHOGENS

RESEARCH ARTICLE

Lyssavirus P-protein selectively targets STAT3-STAT1 heterodimers to modulate cytokine signalling

Angela R. Harrison[1], Kim G. Lieu[2], Florence Larrous[3], Naoto Ito[4], Hervé Bourhy[3], Gregory W. Moseley[1]*

1 Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia, 2 Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Parkville, Victoria, Australia, 3 Lyssavirus Epidemiology and Neuropathology Unit, Institut Pasteur, Paris, France, 4 Laboratory of Zoonotic Diseases, Joint Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan

* greg.moseley@monash.edu

Abstract

Many viruses target *signal transducer and activator of transcription* (STAT) 1 to antagonise antiviral interferon signalling, but targeting of STAT3, a pleiotropic molecule that mediates signalling by diverse cytokines, is poorly understood. Here, using lyssavirus infection, quantitative live cell imaging, innate immune signalling and protein interaction assays, and complementation/depletion of STAT expression, we show that STAT3 antagonism is conserved among P-proteins of diverse pathogenic lyssaviruses and correlates with pathogenesis. Importantly, P-protein targeting of STAT3 involves a highly selective mechanism whereby P-protein antagonises cytokine-activated STAT3-STAT1 heterodimers, but not STAT3 homodimers. RT-qPCR and reporter gene assays indicate that this results in specific modulation of interleukin-6-dependent pathways, effecting differential antagonism of target genes. These data provide novel insights into mechanisms by which viruses can modulate cellular function to support infection through discriminatory targeting of immune signalling complexes. The findings also highlight the potential application of selective interferon-antagonists as tools to delineate signalling by particular STAT complexes, significant not only to pathogen-host interactions but also cell physiology, development and cancer.

Author summary

Lyssaviruses cause rabies, an almost invariably lethal progressive encephalomyelitis responsible for > 60,000 human deaths annually, with no antiviral treatments available. Evasion of host immunity is critical to infection/disease and involves potent suppression of signalling by interferons. However, suppression of responses to other important immune mediators by lyssaviruses and other human pathogenic viruses is poorly understood. Here, we show that the immune antagonist P-protein of diverse pathogenic lyssaviruses inhibits responses activated by interleukin-6 family cytokines, critical players in inflammatory responses, *via* targeting of the host transcription factor STAT3.

Importantly, we find that this involves selective targeting of particular STAT3 signalling complexes, such that P-protein differentially modulates expression of certain interleukin-6-activated host genes. These findings provide new insights into how viruses can 'fine-tune' host immune responses, and into the biological functions of STAT3-complexes, which are currently poorly defined but are significant to immunity, cell physiology and pathologies such as cancer.

Introduction

Rabies is an incurable neurological disease that disproportionately affects children and kills over 60,000 people every year [1–3]. The disease is caused by members of the *Lyssavirus* genus of highly pathogenic non-segmented single-stranded negative-sense RNA viruses, which have been detected on every continent except Antarctica, and include the broadly distributed rabies virus (RABV), as well as Mokola (MOKV) and Duvenhage (DUVV) viruses (identified in Africa), and Australian bat lyssavirus (ABLV) [4]. Lyssaviruses can be transmitted to humans by bites or scratches from infected animals and move through peripheral neurons to infect the central nervous system. Upon reaching the brain, the virus undergoes rapid replication, causing acute and progressive encephalomyelitis [1, 3]. In humans, symptomatic rabies is almost invariably fatal, with no antiviral treatments available or in clinical development. Vaccines in general use for humans and dogs use inactivated virus, and can be effectively applied pre- or post-exposure in humans, provided they are delivered before symptoms develop [3]. However, issues including high cost, a regimen of multiple injections for humans, and the need for delivery of rabies immunoglobulin in post-exposure prophylaxis limit use, particularly in developing nations where most human rabies occurs [1, 2]. Thus, there exists a need to investigate the mechanisms underlying rabies to identify new targets for antiviral drug development or the design of new live-attenuated virus vaccines, which could contribute to control in dogs, the major source of human infection.

In common with other mammalian viruses, evasion of the host antiviral interferon (IFN)-mediated immune response is critical to RABV infection [5–8] and is mediated by virus-encoded IFN-antagonist proteins. A major function of many IFN-antagonists, including the principal RABV antagonist phosphoprotein (P-protein), is the targeting of *signal transducers and activators of transcription (STATs)* 1 and/or 2, the major mediators of signalling by antiviral type I IFN (IFN-α/β) that represents the principal innate antiviral response [9, 10]. The STATs comprise a family of 7 proteins (STAT1-4, STAT5a and STAT5b, and STAT6) that are activated in response to cytokines and other stimuli by phosphorylation at a conserved C-terminal tyrosine. This leads to the formation of parallel dimers, which accumulate within the nucleus and bind to specific DNA elements in the promotor regions of large numbers of target genes, producing distinct profiles depending on the cytokine stimulus and specific STATs activated [11]. RABV P-protein binds directly to STAT1 *via* the P-protein C-terminal domain (CTD) [6, 8, 12], with efficient interaction in cells requiring activation by cytokines [13]. Thus, P-protein interacts strongly with tyrosine-phosphorylated (pY) STAT1-STAT2 heterodimers in IFN-α/β-treated cells, and inhibits nuclear accumulation *via* a nuclear export sequence in the P-protein N-terminus (N-NES), which effects cytoplasmic localisation of the complex [5, 12–14]. P-protein similarly binds and inhibits STAT1 homodimers, the major complex in type II IFN (IFN-γ)-activated cells [12, 14]. STAT1 interaction and N-NES activity is conserved across the *Lyssavirus* genus [15] and highly significant to disease progression *in vivo* [5, 6, 8].

Viral subversion of STAT1/2 signalling is well appreciated due to major roles in the IFN-mediated antiviral response, but an increasing number of viral antagonists are reported to bind/inhibit other STATs including STAT3. STAT3 antagonists include V-protein of several paramyxoviruses [16–18], IE1 of human cytomegalovirus [19], NSP5 of porcine reproductive and respiratory syndrome virus [20], cyclin K of Kaposi's sarcoma-related herpesvirus [21], and P-protein of RABV [22]. STAT3 is activated by IFN-α/β, contributing to the IFN signalling profile, but is also the major mediator of Gp-130-receptor signalling by interleukin-6 (IL-6) cytokine family members [23]. Thus, antagonism of STAT3 is expected to impact an array of innate immune cytokines. Of note, several viral IFN-antagonists that target STAT1 do not target STAT3, and *vice versa*, indicating that interactions are highly specific and virus-dependent [16, 18, 24]. The extent of direct targeting of STAT3 among viruses, however, is poorly characterised, and conservation in lyssaviruses other than RABV is not known.

The diverse cellular roles of STAT3 mean that it is likely to be able to exert antiviral or 'proviral' effects for particular viruses (reviewed in [25, 26]), and many oncoviruses activate STAT3 signalling to influence cell survival/proliferation functions through regulation of a diverse array of genes [27–30]. Interestingly, despite the finding that RABV P-protein encodes STAT3 antagonist function [22], a recent study identified STAT3 as a pro-RABV factor, since RABV infection induced STAT3 phosphorylation, and suppression of STAT3 activity by pharmacological inhibition or siRNA knockdown reduced viral replication [31]. Thus, STAT3 appears likely to have both anti- and pro-viral functions during RABV infection. In common with other STATs, STAT3 forms different transcription factor complexes including STAT3 homodimers and STAT3-STAT1 heterodimers. STAT3 homodimers and heterodimers are likely to enable regulation of distinct gene profiles, as has been suggested for such complexes of other STATs [32–35], and so could account, at least in part, for pro- and anti-viral roles of STAT3. However, despite major roles for STAT3 in human health, including in cancers, the signalling profiles and biological roles of specific STAT3 dimers remains poorly understood. Given the potential divergence in functions of different STAT3 dimers, an intriguing possibility is that selective targeting by viral antagonists might enable suppression of antiviral genes while favouring expression of other genes that support cellular conditions amenable to infection/spread. Furthermore, such targeting could provide new tools to probe the function of specific STAT3 pathways. These possibilities have not been investigated.

Here, we aimed to investigate the lyssavirus P-protein-STAT3 interaction, finding that P-protein uses a novel, dimer-selective strategy to block responses by STAT3-STAT1 heterodimers, but not STAT3 homodimers, and so can exert differential regulation of IL-6-activated genes. This provides insight into the nature of viral regulation of innate immunity, and of differential gene regulation by STAT complexes.

Results

STAT3 is antagonised by P-proteins of diverse lyssaviruses

Previous data indicate that the P-protein of RABV challenge virus standard (CVS) strain (CVS-P) can bind to and inhibit nuclear accumulation of STAT3 following cellular activation by the IL-6 family cytokine oncostatin M (OSM) or by IFN-α, and so suppress OSM-induced gene expression [22]. To examine whether this is conserved between lyssaviruses, we assessed STAT3 antagonism by a panel of P-proteins from viruses including the RABV fixed pathogenic strain Nishigahara (Nish-P) and Nish-derived attenuated strain Ni-CE; the highly pathogenic 'street' strain silver-haired bat rabies virus (SHBRV-P); and the lyssaviruses ABLV, MOKV, and DUVV. The attenuated Ni-CE strain is defective for IFN/STAT1 antagonism due to substitutions in the P gene that inhibit P-protein suppression of STAT1 signalling, including

through deactivation of the N-NES, which disables P-protein-mediated nuclear exclusion of STAT1 [36]. These data indicated that the P-protein is a pathogenesis factor, dependent on its IFN-antagonist function, but effects on responses to other cytokines have not been reported.

COS7 cells expressing P-proteins fused to GFP were treated with OSM before immunofluorescent staining of STAT3 and analysis by confocal laser scanning microscopy (CLSM; Fig 1A) to quantify nucleocytoplasmic localisation of the proteins by calculating the nuclear to cytoplasmic fluorescence ratio (Fn/c, Fig 1B and S1 Fig) [5, 15, 22]. OSM induced clear nuclear accumulation (≥ 2 fold increase in Fn/c) of STAT3 in cells expressing PΔC30 (Fig 1B), a variant of CVS P-protein in which a deletion at the C-terminus prevents interaction with STAT1 or STAT3 [12, 22], and in cells lacking detectable expression of the transfected GFP proteins (S1 Fig). Full-length wildtype (wt) CVS-Pwt was clearly inhibitory (as previously shown [22]), and we confirmed STAT3 antagonist activity in cells treated with IL-6 or IFN-α (S2 Fig). Importantly, P-proteins of all RABV strains (except for the attenuated Ni-CE, see below) and lyssaviruses examined were also inhibitory (Fig 1A and 1B; S1 Fig); this included the distantly related MOKV, indicative of a conserved antagonistic strategy.

All P-proteins except Ni-CE-P localised strongly to the cytoplasm (Fig 1A), consistent with conserved activity of the N-NES [15, 37]. Ni-CE-P displayed more nuclear localisation and, importantly, did not inhibit OSM-induced STAT3 nuclear accumulation (Fig 1B; S1 Fig), similar to previous observations for IFN-activated STAT1 [5]. A significant increase in Ni-CE-P nuclear accumulation was also evident following OSM treatment, accompanying strong nuclear accumulation of STAT3, while OSM treatment had negligible effect on the localisation of other P-proteins (Fig 1B, right panel). Thus, Ni-CE-P appears to be partially relocated to the nucleus by a 'piggyback' mechanism due to association with OSM-activated STAT3 complexes and defective nuclear export; this is again consistent with observations for IFN-activated cells [5]. Thus, lyssavirus P-proteins appear to use a conserved N-NES-dependent strategy to actively export STAT1, 2 and 3 out of the nucleus, which enables antagonism of responses by different cytokine-dependent pathways. Importantly, the finding that Nish and Ni-CE P-proteins differ in antagonism of STAT3 indicates that the capacity to inhibit STAT3 correlates with pathogenicity [5, 38].

Substitutions in the P-protein W-hole impair STAT3 antagonism

Although DUVV-P is inhibitory to STAT3, this activity is significantly reduced compared with other antagonistic P-proteins examined in immunostained cells (Fig 1B, left panel) and living cells co-expressing mCherry-fused STAT3 (Fig 2A and 2B). Analysis of cells infected with RABV and DUVV confirmed a conserved capacity to inhibit STAT3 nuclear accumulation, with the activity of DUVV modestly but significantly reduced (Fig 2C and 2D). DUVV-P was previously shown to be defective for binding to STAT1 compared with P-proteins of other lyssaviruses, which appears to relate to a substitution in the 'W-hole' hydrophobic pocket in the P-protein CTD (W265 in RABV P-protein for G265 in DUVV P-protein) [6]. Combined substitution of two residues (W265 to G and M287 to V; W265G/M287V) in the W-hole of RABV or DUVV P-proteins strongly impairs IFN/STAT1 binding/antagonism and pathogenesis of recombinant RABV [6]. Notably, analysis by CLSM of immunostained and living cells expressing CVS P-protein containing W265G/M287V substitutions (CVS-Pmut) revealed clear loss of antagonism toward OSM-induced STAT3 nuclear accumulation (Fig 3A–3D). Analysis of immunoprecipitates of GFP-P-proteins from HEK293T cells (Fig 3E) indicated that CVS-Pwt clearly co-precipitates STAT3 from OSM and IFN-α-treated cells, with efficient co-precipitation requiring activation/phosphorylation of STAT3, as expected [22]. PΔC30 and CVS-Pmut were strongly impaired for interaction. These data indicate that STAT3 is bound

Fig 1. P-proteins from diverse lyssaviruses inhibit STAT3 responses to OSM. (A) COS7 cells transfected to express the indicated proteins were treated 24 h post-transfection with or without (No add.) OSM (10 ng/ml, 15 min) before fixation, immunofluorescent staining for STAT3 (red) and analysis by CLSM. Representative images are shown. Arrowheads indicate cells with detectable expression of the transfected protein. Scale bars, 30 μm. (B) Images such as those shown in A were analysed to calculate the ratio of nuclear to cytoplasmic fluorescence (Fn/c) for STAT3 (left panel) and P-proteins (right panel) in GFP-positive cells; histograms show mean ± standard error of the mean (SEM; n ≥ 47 cells for each condition; results are from a single assay representative of three independent assays). Statistical analysis used Student's t test. ****, p < 0.0001; NS, not significant; No add., no addition. Cells lacking detectable expression of the transfected protein were also analysed to determine the Fn/c for STAT3 as an internal negative control (see S1 Fig).

Fig 2. DUVV is defective for STAT3 antagonism compared with RABV. (A) COS7 cells co-transfected to express the indicated proteins were treated 24 h post-transfection with or without OSM (10 ng/ml, 30 min) before live-cell CLSM. (B) Images such as those shown in A were analysed to calculate the Fn/c for STAT3-mCherry (mean ± SEM; n ≥ 68 cells for each condition; results are from a single assay representative of two independent assays). (C,D) HeLa cells infected with CVS or DUVV (MOI of 1) or mock-infected were treated 48 h post-infection with or without OSM (10 ng/ml, 45 min) before fixation, staining for P-protein (green) and pY-STAT3 (red) and immunofluorescence analysis (C) to determine the Fn/c for pY-STAT3 (D; mean ± SEM, n ≥ 13 cells). Arrowheads indicate cells in which infection was clearly detectable. Scale bars, 30 μm. Statistical analysis used Student's t test. *, p < 0.05; ****, p < 0.0001.

Fig 3. Mutation of RABV P-protein residues W265 and M287 prevents antagonism of STAT3. (A) COS7 cells transfected to express the indicated proteins were treated with or without OSM before immunofluorescent staining for STAT3 and analysis by CLSM, as described in the legend to Fig 1. Representative images are shown. Arrowheads indicate cells with detectable expression of the transfected protein. (B) Images such as those shown in A were analysed to calculate the Fn/c for STAT3 (mean ± SEM; n ≥ 31 cells for each condition; results are from a single assay representative of four independent assays). (C,D) COS7 cells co-transfected to express the indicated proteins were treated with or without OSM before live-cell CLSM (C) to determine the Fn/c for STAT3-mCherry (D; mean ± SEM; n ≥ 59 cells for each condition; results are from a single assay representative of two independent assays), as described in the legend to Fig 2. Scale bars, 30 μm. Statistical analysis used Student's *t* test. ****, p < 0.0001. (E) HEK293T cells transfected to express the indicated proteins were treated 24 h post-transfection with or without OSM (10 ng/ml, 15 min) or IFN-α (1,000 U/ml, 30 min) before lysis and immunoprecipitation for GFP. Lysates (input) and immunoprecipitates (IP) were analysed by immunoblotting (IB) using antibodies against the indicated proteins. Results are representative of 3 independent assays.

by the P-protein CTD in an analogous fashion to STAT1, and likely involves the same or over-lapping regions.

Antagonism of OSM-activated genes differs between RABV P-protein and mumps virus V-protein

The above data suggested two likely possibilities. In the first, P-protein binds to a conserved/homologous site on STAT1 and STAT3 to directly antagonise both proteins, a reasonable scenario given the high degree of similarity in STAT1/3 domain structure and sequence [39] (72% protein sequence similarity). Such independent targeting of STAT1 and STAT3 was reported for mumps virus (MUV) V-protein, which induces degradation of both proteins [16, 40]. Alternatively, RABV P-protein CTD directly targets STAT1 (as confirmed recently using biophysical techniques [8]), but does not specifically contact STAT3 and rather interacts with STAT3 in the context of activated STAT3-STAT1 heterodimers. The latter is intriguing as it could result in selective antagonism of IL-6-activated pY-STAT3-STAT1 heterodimers without impacting on distinct pY-STAT3 complexes such as STAT3 homodimers, potentially resulting in selective gene regulation. Interestingly, despite more potent activation of STAT3 by OSM compared with IFN-α (see pY-STAT3 levels in input, Fig 3E), CVS-Pwt clearly co-precipitated more STAT3 in response to IFN-α than OSM. IFN-α is a potent activator of STAT1, and we confirmed that IFN-α treatment induced higher levels of pY-STAT1 than OSM, in direct contrast to induction of pY-STAT3 (S3 Fig). These data suggested that IFN-α will induce higher levels of STAT3-STAT1 heterodimers than OSM; thus, the greater co-precipitation of STAT3 with P-protein from IFN-α-activated cells would appear consistent with targeting *via* activated STAT1.

The specific roles of STAT3 heterodimers and homodimers in regulating IL-6 cytokine-inducible genes are poorly understood. However, maximal induction of the STAT3 target gene *c-fos* in response to OSM was found to be dependent on the expression of both STAT3 and STAT1 [41]. Furthermore, electrophoretic mobility shift assays (EMSA) indicated that IL-6 induces substantial binding of STAT3 homodimers and STAT3-STAT1 heterodimers to the m67 probe, which is a variant of a STAT-binding sequence derived from the *c-fos* promoter [42–44]. In contrast, EMSA analyses indicated that the promoter of *socs3*, a well-established IL-6/STAT3 target gene, appears to be predominantly bound by STAT3 homodimers in response to IL-6 or the IL-6 family cytokine leukaemia inhibitory factor [45, 46]. We reasoned that these genes might be induced to differing extents by STAT3-STAT1 and STAT3-STAT3 complexes, with *socs3* largely affected by the latter. Thus, MUV V-protein would be expected to inhibit OSM-dependent *socs3* expression, but RABV P-protein might differ, depending on whether it binds STAT3 directly or only in the context of STAT3-STAT1 complexes. We thus performed RT-qPCR analysis of *socs3* expression, confirming substantial upregulation by OSM, which was clearly inhibited by MUV V-protein (Fig 4). However, RABV P-protein had no inhibitory effect across multiple assays. In contrast, P-protein was able to suppress *c-fos* activation by OSM (Fig 4). These data indicated that RABV P-protein and MUV V-protein differ in their capacity to target specific genes, possibly due to distinct targeting of STAT3 dimers by P-protein.

RABV P-protein-STAT3 interaction is dependent on STAT1

To directly examine the role of STAT3-STAT1 complexes in STAT3 targeting by P-protein, we used 2fTGH cells and a 2fTGH-derivative STAT1-null line, U3A, which have been used extensively to study STAT1 function (eg. [47, 48]). CLSM analysis of living cells expressing STAT3-mCherry indicated that CVS-Pwt strongly inhibits OSM-induced STAT3 responses in

Fig 4. RABV P-protein and MUV V-protein differentially regulate OSM/STAT3-activated target genes. HEK293T cells transfected to express the indicated proteins were treated 24 h post-transfection with or without OSM (10 ng/ml, 45 min for *socs3*, 60 min for *c-fos*) before analysis by RT-qPCR. Histograms show expression of *socs3* and *c-fos* normalised to *gapdh* and calculated relative to that determined for untreated GFP-N-protein-expressing cells (mean ± SEM; n = 3 independent assays). GFP-N, GFP-RABV CVS nucleoprotein; *, p < 0.05; **, p < 0.01; NS, not significant.

2fTGH but has no effect in U3A cells (Fig 5A and 5B). Consistent with this, immunoprecipitation assays indicated that OSM-activated STAT3 and STAT1 co-precipitate with CVS-Pwt from 2fTGH but not U3A cells (Fig 5C; S4 Fig). Furthermore, reporter gene assays for IL-6-induced gene expression (using the m67-luciferase plasmid, as previously [22]) indicated that CVS-Pwt effects significant inhibition of OSM signalling in 2fTGH cells but not U3A cells (Fig 6). Similar inhibition was observed in HEK293T cells, which also express STAT1 (S5 Fig). Thus it appears that P-protein-STAT3 interaction requires STAT1, consistent with selective targeting of STAT3-STAT1 complexes. In contrast, MUV V-protein strongly inhibited luciferase induction in all cell types (Fig 6; S5 Fig), consistent with independent targeting of STAT3 and STAT1.

Of note, these assays indicated that the extent of antagonism in STAT1-positive cells differs between RABV P-protein and MUV V-protein (Fig 6; S5 Fig), possibly relating to differential targeting of STAT complexes. This difference observed in the reporter assays was not clearly evident in RT-qPCR analysis of *c-fos* expression (Fig 4). This is perhaps due to differences in the nature of the assays, where the former detects protein expression 8 h post-OSM treatment from plasmid carrying m67 (an enhanced variant of a minimal STAT-binding sequence of the *c-fos* promoter [44]), and the latter detects transcript induced from the endogenous *c-fos* gene soon after treatment; thus, the extent and kinetics of promoter interaction with STAT dimers might differ. However, the data together clearly indicate that P-protein inhibits OSM-activated gene expression dependent on STAT1 (Fig 6), and differentially impacts expression of specific endogenous target genes (Fig 4).

Importantly, the capacity of an IFN-antagonist to bind STAT1 does not *per se* confer binding to STAT3, as reported for Hendra virus (HENV) V-protein [24], which binds STAT1 and STAT2 independently of tyrosine phosphorylation and inhibits nuclear translocation in response to IFN, but does not co-precipitate with STAT3 from non-activated cells [24]. To

Fig 5. RABV P-protein does not interact with STAT3 in STAT1-deficient U3A cells. (A,B) 2fTGH and U3A cells co-transfected to express the indicated proteins were treated with or without OSM before live-cell CLSM (A) to determine the Fn/c for STAT3-mCherry (B; mean ± SEM; n > 71 cells for each condition; results are from a single assay representative of two independent assays), as described in the legend to Fig 2. Scale bars, 30 μm. Statistical analysis used Student's *t* test. ****, p < 0.0001; NS, not significant. (C) 2fTGH and U3A cells transfected to express GFP-CVS-Pwt were treated with or without OSM before immunoprecipitation of GFP and analysis by IB using antibodies against the indicated proteins, as described in the legend to Fig 3. Results are representative of 3 independent assays.

https://doi.org/10.1371/journal.ppat.1008767.g005

confirm the lack of STAT3 interaction in cytokine-activated cells, we assessed OSM-activated STAT3 nuclear localisation in COS7 cells, finding the HENV V-protein, which is exclusively cytoplasmic, has no inhibitory effect, in contrast to MUV V-protein and RABV P-protein (S6 Fig). We saw consistent results in HeLa cells (S6 Fig), indicating that the lack of STAT3 targeting is not due to host species/cell type. Thus, STAT1-dependent targeting of STAT3 by RABV P-protein represents a specific mechanism.

To confirm directly the dependence of STAT3 antagonism by P-protein on STAT1, we reconstituted STAT1 expression in U3A cells by co-transfection to express mCherry-STAT1 or expression controls (mCherry alone or mCherry-STAT3). CLSM analysis of cells immunostained for STAT3 indicated that STAT1 expression is sufficient to recapitulate antagonism of OSM-activated STAT3 by CVS-Pwt, with the extent of STAT3 inhibition comparable to that in 2fTGH cells (Fig 7A and 7B). Importantly, we saw no comparable effect of STAT3 overexpression. Thus, the effect of STAT1 expression is not simply due to increased cellular levels of

Fig 6. Antagonism of STAT3 by RABV P-protein is defective in STAT1-deficient U3A cells. 2fTGH or U3A cells co-transfected with m67-LUC and pRL-TK plasmids, and plasmids to express the indicated proteins, were treated 16 h post-transfection with or without OSM (10 ng/ml, 8 h) before determination of relative luciferase activity (mean ± SEM; n = 3 independent assays, upper panel); *lower panel*: cell lysates used in a representative assay were analysed by IB for GFP. Statistical analysis used Student's *t* test. **, p < 0.01; ****, p < 0.0001; NS, not significant.

STAT complexes, with the data directly supporting the idea that P-protein targets STAT3-STAT1 heterodimers, but not STAT3 homodimers.

We further analysed P-protein-STAT3 interaction by immunoprecipitation using a tetracy-cline-inducible stable transfection system to express non-fused STAT1 in U3A cells, confirming that STAT1 expression clearly enhanced co-precipitation of pY-STAT3 with CVS-Pwt (Fig 7C). Finally, knockdown of STAT1 in 2fTGH cells using siRNA (Fig 8A) impaired antagonistic activity of CVS-Pwt toward OSM-activated STAT3 nuclear accumulation (Fig 8B and 8C). STAT1 knockdown also clearly reduced OSM-dependent interaction of CVS-Pwt with STAT3 (Fig 8D); although the loss of STAT3 interaction was not complete, the observed reduction of interaction is consistent with the observed knockdown of STAT1 (Fig 8A). Together these data using U3A and 2fTGH, and different methods to reduce or increase expression of STATs, indicate that the lack of STAT3 targeting by P-protein in U3A is due to the absence of STAT1, rather than other parameters such as differing basal STAT3 expression levels. Thus, P-protein requires STAT1 to antagonise STAT3, consistent with selective targeting of STAT1 and, thereby, STAT3-STAT1 heterodimers, but not STAT3 homodimers.

Discussion

Here we have shown that antagonism of STAT3 is conserved among P-proteins from diverse, highly lethal lyssaviruses, including the RABV street strain SHBRV and the closely related

Fig 7. RABV P-protein antagonism of STAT3 is restored in U3A cells by STAT1 expression. (A) 2fTGH and U3A cells co-transfected to express the indicated proteins were treated with or without OSM (10 ng/ml, 30 min) before fixation, immunofluorescent staining for STAT3 (blue, Alexa Fluor 647) and analysis by CLSM, as described in the legend to Fig 1. Representative images are shown. Arrowheads indicate cells with detectable expression of transfected proteins. Scale bars, 30 μm. (B) Images such as those shown in A were analysed to calculate the Fn/c for STAT3

(mean ± SEM; n ≥ 40 cells for each condition; results are from a single assay representative of three independent assays). Statistical analysis used Student's *t* test. ****, p < 0.0001; NS, not significant. (C) U3A cells stably transfected with plasmid for tetracycline-inducible expression of STAT1 were cultured with or without 1 μg/ml tetracycline (Tet) to induce STAT1 expression and transfected to express GFP or GFP-CVS-Pwt. Cells were treated 24 h post-transfection with or without OSM before immunoprecipitation of GFP and analysis by IB, as described in the legend to Fig 3. Results are representative of two independent assays.

ABLV (RABV and ABLV are members of *Lyssavirus* phylogroup I), as well as the distantly related MOKV of phylogroup II, indicative of conserved roles in lyssavirus infection. Thus, lyssaviruses form part of a limited cohort of negative-sense RNA viruses shown to target STAT3,


Fig 8. RABV P-protein antagonism of STAT3 is impaired by depletion of STAT1. (A) 2fTGH cells were transfected with 100 nM scrambled siRNA or siRNA specific for STAT1 (STAT1 siRNA) for 48 h before lysis and IB analysis using antibodies against the indicated proteins. Actin was used as loading control. (B) 2fTGH cells were transfected with siRNA (as described in A) for 24 h before transfection to express the indicated protein for a further 24 h. Cells were then treated with or without OSM before immunofluorescent staining for STAT3 (red) and analysis by CLSM as described in the legend to Fig 1. Representative images are shown. Arrowheads indicate cells with detectable expression of the transfected protein. Scale bars, 30 μm. (C) Images such as those shown in B were analysed to calculate the Fn/c for STAT3 (mean ± SEM; n ≥ 55 cells for each condition; results are from a single assay representative of two independent assays). Statistical analysis used Student's *t* test. ****, p < 0.0001; NS, not significant. (D) 2fTGH cells transfected with siRNA and plasmids to express the indicated proteins (as described in B) were treated with or without OSM before immunoprecipitation of GFP and analysis by IB as described in the legend to Fig 3. Results are representative of four independent assays.

which includes the paramyxoviruses MUV, measles and Tioman virus [16–18]. Together with reports of STAT3 antagonism by more diverse viruses including double-stranded DNA [19] and positive-sense RNA viruses [20], these data suggest that STAT3 targeting has important and likely highly specific roles in the biology of certain viruses. This likely involves antagonism of signalling by a broad array of cytokines that signal via STAT3, including IL-6 cytokine family members (e.g. IL-6, leukaemia inhibitory factor and ciliary neurotrophic factor), IFNs, IL-10, IL-2, IL-22, granulocyte-macrophage colony-stimulating factor and epidermal growth factor [26]. Selective evasion of multiple cytokine pathways may be of particular importance to lyssaviruses due to their broad host range, infection of multiple organs/cell types and often lengthy incubation [1, 4, 49].

We found that the efficiency of targeting/antagonism of STAT3 differs between specific lyssaviruses and attenuated RABV, correlating with differing targeting efficiency toward STAT1 [5, 6], and that this is due to the interaction with STAT3 being mediated indirectly *via* STAT1 in the context of STAT3-STAT1 heterodimers. Importantly, targeting of STAT1 does not necessarily confer to IFN-antagonists the capacity to interact with STAT3, as shown here and previously for V-proteins of paramyxoviruses HENV, Nipah virus and simian virus 5 (S6 Fig) [16, 24]. Thus, it appears that P-protein specifically inhibits STAT3-STAT1 heterodimers but not STAT3 homodimers such that signalling by the latter would be unimpaired. In fact, although CVS-Pwt clearly and consistently suppressed OSM signalling leading to luciferase expression from the m67-LUC plasmid in 2fTGH cells (and HEK293T cells), its effect was partial compared with MUV-V, which resulted in signalling approaching or equivalent to that in non-treated cells (Fig 6 and S5 Fig). This is consistent with a global shut-down of STAT3 signalling by MUV V-protein compared with targeting of a subset of signalling complexes (i.e. STAT3-STAT1 heterodimers) by P-protein. Indeed, RT-qPCR analysis indicated that P-protein selectively regulates gene expression in response to OSM, being able to inhibit *c-fos* but not *socs3* expression.

The specific biological roles of STAT3-STAT1 heterodimers and most other STAT heterodimers are poorly understood [32]. Perhaps the best characterised STAT heterodimer is STAT1-STAT2, which is activated by type I IFNs and, in complex with IFN regulatory factor 9, binds to IFN-stimulated response elements within IFN-stimulated gene (ISG) promoters to activate transcription. In contrast, STAT1 homodimers, which are activated by both type I and II IFNs, bind to gamma-activated sequences (GAS) within a distinct but overlapping set of ISGs. STAT1-STAT2 heterodimers are therefore a major determinant of the distinct outcomes of type I and type II IFN signalling [33]. Direct evidence for functional differences of other pairs of STAT homo/heterodimers is very limited. A ChIP-reChIP analysis found that the *ebi3* and *il12a* promoters are strongly bound by IL-35-activated STAT1-STAT4 heterodimers but not by STAT1 or STAT4 homodimers (activated by IFN-γ or IL-12, respectively) [34]. Consistent with this, expression of both STAT1 and STAT4 was required for maximal induction of *ebi3* and *il12a* by IL-35. Importantly, the STAT1-STAT4 heterodimer did not bind to the promoters of classical STAT1 and STAT4 target genes *irf1* and *il18ra*, respectively; together, these data suggest that STAT1-STAT4 complexes likely regulate gene profiles distinct from those regulated by STAT1 or STAT4 homodimers [34]. Similarly, EMSA analysis of STAT-DNA complexes formed in response to colony stimulating factor 1 and platelet-derived growth factor found that STAT3-STAT5 heterodimers interacted with the m67 probe but not the prolactin-inducible element from the bovine casein gene promoter, which was bound by STAT5 homodimers [35].

Clear evidence for gene-specific binding or regulation is lacking for STAT3-STAT1 complexes. While there are contrasting reports on whether STAT3 plays a positive or negative role in IFN signalling [50–59], one study proposed that STAT3 sequesters STAT1 in

STAT3-STAT1 heterodimers and thereby reduces the amount of STAT1 homodimers bound to DNA in response to IFN-α, inhibiting the activation of certain GAS-containing ISGs (*irf1*, *cxcl9* and *cxcl10*) [55]. This implies that STAT3-STAT1 heterodimers may not be as effective at inducing these ISGs as STAT1 homodimers [55]. Nevertheless, our data using viral proteins specific for different STAT3 dimers is the first to indicate that STAT3-STAT1 heterodimers and STAT3 homodimers differentially contribute to gene expression. Specifically, the RT-qPCR assays indicated that OSM-induced *socs3* expression is suppressed by MUV V-protein but is unaffected by RABV P-protein, and thus likely to be largely induced by STAT3 homodimers. In contrast, the m67 luciferase and *c-fos* RT-qPCR assays indicate that *c-fos* expression is mediated, at least in part, by STAT3-STAT1 heterodimers, as it is inhibited by P-protein. Together these data support the idea that STAT heterodimers provide specific mechanisms to regulate particular functional genes and gene subsets, enabling fine-tuning of transcription and cellular responses; the formation of heterodimers, and hence functional outcomes, are likely influenced by factors including the integration of pathways activated by different cyto-kines acting on a cell at a given time, the expression levels of specific STAT members, and the type of cell. Moreover, the data support the utility of viral proteins that selectively target specific STATs/STAT complexes, such as HENV and MUV V-proteins, and RABV P-protein, as tools to delineate specific STAT signalling pathways.

While the full extent of the distinct functions of STAT3-STAT1 and STAT3-STAT3 dimers await further research, the biological impact of dimer selective targeting by P-protein is likely to be complex. STAT3 is implicated in antiviral immunity [50–52, 60, 61], inflammation [62, 63], cell survival and proliferation [64–66], and in regulating mitochondrial activity [67], autophagy [68], and microtubule stability [69, 70]. Because of this, global shutdown of STAT3 by virus is likely not only to impact antiviral pathways, but also cellular homeostasis more generally, impacting viability. This is likely to be more readily tolerated, or even beneficial for viruses with rapid replication cycles, but would be detrimental to lyssavirus infection that can have long incubation periods and relies on intact neuronal networks for viral entry and egress of the central nervous system [71]. Indeed, a lack of neuropathological damage indicative of "stealthy" infection of cells is a hallmark of RABV-infected brain samples [49, 72–74]. Selective targeting of activated (phosphorylated) STATs ([13, 22] and this study), combined with specificity for particular complexes is likely to support this, preventing 'wholesale' shutdown characteristic of some viruses, but enabling inhibition of induced antiviral mechanisms (mediated by STAT1/2 complexes and potentially STAT3-STAT1 complexes), without impacting homeostasis (potentially requiring STAT3 homodimers). The idea of a pro-RABV role for STAT3 complexes (likely STAT3 homodimers) is supported by recent data indicating that inhibition of STAT3 activity can impair RABV replication [31].

The great diversity in IFN-antagonist mechanisms used by viruses is likely to derive from specifics of the life cycle, including the duration of incubation and replication cycles, and cell tropism, such that closely related viruses including RABV and vesicular stomatitis virus use very different strategies [75]. The evolution of selective STAT targeting likely has similar evolutionary sources, with our data indicating selectivity not only between STAT family members, but also the dimers formed. Systems genomic analysis of the effects of P-protein on global cytokine/STAT3-dependent gene expression should expand our understanding of how this selective targeting modifies cellular functions, as well as the precise mechanisms of specific gene regulation by STAT3 complexes, a fundamental yet poorly understood aspect of cell biology important to immunity, development and cancer. Such knowledge would be hoped to contribute to efforts to develop novel viral vaccines and, potentially, antivirals, as well as approaches for STAT3-related pathologies such as cancer.

Materials and methods

Plasmids and cell culture

The construct to express MUV-V fused to GFP was generated by PCR amplification from MUV V-FLAG (a gift from Curt Horvath [16], Addgene plasmid #44908) and cloning into the pEGFP-C1 vector C-terminal to GFP (Clontech). STAT1 expression constructs were generated by PCR amplification from STAT1 plasmid and cloning into the pmCherry-N3 vector or the tetracycline-inducible expression vector pEBTetD (a gift from Dirk Gründemann, University of Cologne [76]). The construct to express mCherry-fused STAT3 was a kind gift from Marie Bogoyevitch (University of Melbourne). Other constructs have been described elsewhere [6, 15, 22].

2fTGH and U3A cells were a kind gift from George Stark, Lerner Research Institute, Cleveland Clinic. 2fTGH, U3A, COS7, HeLa and HEK293T cells were maintained in DMEM supplemented with 10% FCS and GlutaMAX (Life Technologies), 5% CO_2, 37˚C. Plasmid transfections used Lipofectamine 2000 (Invitrogen) or FuGene HD (Promega), according to the manufacturer's instructions. siRNA (100 nM) was reverse-transfected into 2fTGH cells using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. U3A cells stably transfected with pEBTetD-STAT1 were cultured with 1 μg/ml tetracycline to induce STAT1 expression.

Microscopy

For analysis of STAT3 and P-protein localisation, cells growing on coverslips transfected with plasmids or infected with RABV (strain CVS; MOI of 1) or DUVV (strain 86132SA; MOI of 1) were incubated in serum-free-(SF)-DMEM for 1 h and treated without or with 10 ng/mL recombinant human OSM (BioVision) for 15 min (analysis of endogenous STAT3 in immunostained transfected cells), 30 min (analysis of STAT3-mCherry in living or immunostained transfected cells) or 45 min (analysis of infected cells). Cells were then fixed using 3.7% formaldehyde (10 min, room temperature, RT) followed by 90% methanol (5 min, RT) for transfected cells or cold methanol followed by 80% acetone for infected cells and immunostained. Antibodies used were: anti-STAT3 (Santa Cruz, sc-482), anti-pY-STAT3 (Cell Signaling Technology, 9145), anti-P-protein [77] and Alexa Fluor 488, 568 and 647 secondary antibodies (ThermoFisher Scientific).

Transfected cells were analysed by CLSM using a Leica SP5 or Nikon C1 Inverted confocal microscope with 63 X objective. For live cell analysis, cells were imaged in phenol-free DMEM using a heated chamber. Infected cells were analysed using a Zeiss Axioplan (version 2.2) fluorescence microscope equipped with a Zeiss ApoTome system, as previously [15]. Digitised confocal images were processed using Fiji software (NIH). To quantify nucleocytoplasmic localisation, the ratio of nuclear to cytoplasmic fluorescence, corrected for background fluorescence (Fn/c), was calculated for individual cells [15, 22].

Co-immunoprecipitation

Transfected cells were incubated in SF-DMEM (3 h) before treatment with or without OSM (10 ng/ml, 15 min) or IFN-α (Universal Type I IFN, PBL Assay Science, 1000 U/ml, 30 min), lysis and immunoprecipitation using GFP-Trap Agarose beads (Chromotek), according to the manufacturer's instructions. Lysis and wash buffers were supplemented with PhosSTOP (Roche), cOmplete Protease Inhibitor Cocktail (Roche) and 10 mM NaF. Lysates and immunoprecipitates were analysed by SDS-PAGE and immunoblotting (IB) using antibodies against STAT3 (above), pY-STAT3 (above), STAT1 (BD Biosciences, 610119 or 610185), pY-STAT1

(Cell Signaling Technology, 9167 or Santa Cruz, sc-7988), GFP (Roche Applied Science, 11814460001), actin (Abcam, ab3280) and HRP-conjugated secondary antibodies (Merck). Visualisation of bands used Western Lightning chemiluminescence reagents (PerkinElmer).

Luciferase reporter gene assays

Cells were co-transfected with Firefly luciferase plasmid m67-LUC and Renilla luciferase plasmid pRL-TK, as previously described [22], and protein expression constructs for 16 h. Cells were then treated without or with OSM (10 ng/mL, 8 h) before lysis using Passive Lysis Buffer (Promega). Firefly and Renilla luciferase activity was determined in a dual luciferase assay, as previously described [6, 22]. The ratio of Firefly to Renilla luciferase activity was determined for each condition, and then calculated relative to that determined for GFP-N-protein-expressing cells treated with OSM (relative luciferase activity). Data from ≥ 3 independent assays were combined, where each assay result is the mean of three replicate samples.

RT-qPCR

Transfected HEK293T cells were incubated in SF-DMEM (3 h) before treatment without or with OSM (10 ng/ml, 45 min for *socs3*, 60 min for *c-fos*) and RNA extraction (ReliaPrep RNA Cell Miniprep System, Promega). cDNA was generated using oligo(dT)$_{20}$ primer (GoScript Reverse Transcription System, Promega), before qPCR using primers for *socs3*, *c-fos* and *gapdh*, and iTaq Universal SYBR Green Supermix (Bio-Rad). Standard curves were generated for each primer pair using serial dilutions of the reference cDNA (samples from GFP-N-protein-expressing cells treated with OSM). Values were normalised to *gapdh* [6] and then calculated relative to that determined for untreated GFP-N-protein-expressing cells. Data from 3 independent assays were combined, where each assay result is the mean of replicate samples. Primers sequences were: 5'-GGTGCATTACAGAGAGGAGAAA-3' and 5' GTGTGTTTCA CGCACAGATAAG-3' for *c-fos;* 5'-GGAGTTCCTGGACCAGTACG-3' and 5'-TTCTTGTG CTTGTGCCATGT-3' for *socs3*; 5'-GAAGGTGAAGGTCGGAGTC-3' and 5'-GGTCATGA GTCCTTCCACGAT-3' for *gapdh*.

Statistical analysis

Unpaired two-tailed Student's *t*-test was performed using Prism software (version 7, GraphPad).

Supporting information

S1 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data for Fig panels 1B and S1, 2B, 2D, 3B, 3D, 4, 5B, 6, 7B, 8C, S2B, S5 and S6B.
(XLSX)

S1 Fig. Fn/c analysis of STAT3 in transfected cells lacking detectable expression of GFP. Images of COS7 cells used for the analysis shown in Fig 1 were analysed to determine the Fn/c for immunostained STAT3 in cells lacking detectable expression of the GFP-fused protein (GFP -) (mean ± SEM; n $\geq$ 33 cells for each condition). GFP + indicates analysis of cells with detectable GFP expression (data from Fig 1B, shown for comparison). Statistical analysis used Student's *t* test. ****, p < 0.0001; NS, not significant.
(TIF)

S2 Fig. RABV P-protein inhibits STAT3 responses to OSM, IL-6 and IFN-α. (A) COS7 cells transfected to express the indicated proteins were treated with or without OSM (10 ng/ml), IL-

6 (100 ng/ml) or IFN-α (1000 U/ml) for 15 min before immunofluorescent staining for STAT3 (red) and analysis by CLSM as described in the legend to Fig 1. Representative images are shown. Arrowheads indicate cells with detectable expression of the transfected protein. Scale bars, 30 μm. (B) Images such as those shown in A were analysed to calculate the Fn/c for STAT3 (mean ± SEM, n ≥ 103 cells for each condition). Statistical analysis used Student's *t* test. ****, $p < 0.0001$; NS, not significant.
(TIF)

S3 Fig. STAT1 and STAT3 are activated to different extents by OSM and IFN-α. HEK293T cells were treated with or without OSM or IFN-α before lysis and IB analysis using antibodies against the indicated proteins, as described in the legend to Fig 3.
(TIF)

S4 Fig. RABV P-protein interacts with STAT1 in OSM-treated 2fTGH cells. 2fTGH and U3A cells transfected to express GFP-CVS-Pwt were treated with or without OSM before immunoprecipitation of GFP and IB analysis using antibodies against the indicated proteins, as described in the legend to Fig 3. Results are from a single blot with intervening and marker lanes removed.
(TIF)

S5 Fig. RABV P-protein antagonises OSM/STAT3-dependent gene expression. HEK293T cells co-transfected with m67-LUC and pRL-TK plasmids, and plasmids to express the indicated proteins, were treated with or without OSM before determination of relative luciferase activity (mean ± SEM; n = 4 independent assays, upper panel), as described in the legend to Fig 6; *lower panel*: cell lysates used in a representative assay were analysed by IB for GFP. Statistical analysis used Student's *t* test. **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.
(TIF)

S6 Fig. Viral IFN-antagonists differentially regulate STAT3 responses to OSM. (A) COS7 and HeLa cells transfected to express the indicated proteins were treated with or without OSM before immunofluorescent staining for STAT3 (red) and analysis by CLSM as described in the legend to Fig 1. Representative images are shown. Arrowheads indicate cells with detectable expression of the transfected protein. Scale bars, 30 μm. (B) Images such as those shown in A were analysed to calculate the Fn/c for STAT3 (mean ± SEM, n ≥ 35 cells for each condition). Statistical analysis used Student's *t* test. ****, $p < 0.0001$; NS, not significant.
(TIF)

Author Contributions

Conceptualization: Angela R. Harrison, Gregory W. Moseley.

Data curation: Angela R. Harrison, Gregory W. Moseley.

Formal analysis: Angela R. Harrison, Kim G. Lieu, Florence Larrous.

Funding acquisition: Hervé Bourhy, Gregory W. Moseley.

Investigation: Angela R. Harrison, Kim G. Lieu, Florence Larrous.

Methodology: Angela R. Harrison, Kim G. Lieu, Florence Larrous, Naoto Ito, Hervé Bourhy, Gregory W. Moseley.

Project administration: Hervé Bourhy, Gregory W. Moseley.

Resources: Naoto Ito, Hervé Bourhy, Gregory W. Moseley.

Supervision: Hervé Bourhy, Gregory W. Moseley.

Validation: Angela R. Harrison, Kim G. Lieu, Florence Larrous.

Visualization: Angela R. Harrison.

Writing – original draft: Angela R. Harrison.

Writing – review & editing: Angela R. Harrison, Kim G. Lieu, Florence Larrous, Naoto Ito, Hervé Bourhy, Gregory W. Moseley.

References

1. World Health Organization. WHO Expert Consultation on Rabies: second report. Geneva, Switzerland: 2013.

2. Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015; 9(4):e0003709. https://doi.org/10.1371/journal.pntd.0003709 PMID: 25881058

3. Fooks AR, Cliquet F, Finke S, Freuling C, Hemachudha T, Mani RS, et al. Rabies. Nature Reviews Disease Primers. 2017; 3(1):17091.

4. Warrell MJ, Warrell DA. Rabies and other lyssavirus diseases. The Lancet. 2004; 363(9413):959–69.

5. Ito N, Moseley GW, Blondel D, Shimizu K, Rowe CL, Ito Y, et al. Role of interferon antagonist activity of rabies virus phosphoprotein in viral pathogenicity. Journal of virology. 2010; 84(13):6699–710. https://doi.org/10.1128/JVI.00011-10 PMID: 20427527

6. Wiltzer L, Okada K, Yamaoka S, Larrous F, Kuusisto HV, Sugiyama M, et al. Interaction of Rabies Virus P-Protein With STAT Proteins is Critical to Lethal Rabies Disease. The Journal of infectious diseases. 2014; 209(11):1744–53. https://doi.org/10.1093/infdis/jit829 PMID: 24367042

7. Rieder M, Brzozka K, Pfaller CK, Cox JH, Stitz L, Conzelmann KK. Genetic dissection of interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 activation is important for pathogenicity. Journal of virology. 2011; 85(2):842–52. https://doi.org/10.1128/JVI.01427-10 PMID: 21084487

8. Hossain MA, Larrous F, Rawlinson SM, Zhan J, Sethi A, Ibrahim Y, et al. Structural Elucidation of Viral Antagonism of Innate Immunity at the STAT1 Interface. Cell Rep. 2019; 29(7):1934–45 e8. https://doi.org/10.1016/j.celrep.2019.10.020 PMID: 31722208

9. Versteeg GA, Garcia-Sastre A. Viral tricks to grid-lock the type I interferon system. Current opinion in microbiology. 2010; 13(4):508–16. https://doi.org/10.1016/j.mib.2010.05.009 PMID: 20538505

10. Hoffmann HH, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 2015; 36(3):124–38. https://doi.org/10.1016/j.it.2015.01.004 PMID: 25704559

11. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012; 30(2):88–106. https://doi.org/10.3109/08977194.2012.660936 PMID: 22339650

12. Vidy A, Chelbi-Alix M, Blondel D. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. Journal of virology. 2005; 79(22):14411–20. https://doi.org/10.1128/JVI.79.22.14411-14420.2005 PMID: 16254375

13. Brzozka K, Finke S, Conzelmann KK. Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. Journal of virology. 2006; 80(6):2675–83. https://doi.org/10.1128/JVI.80.6.2675-2683.2006 PMID: 16501077

14. Vidy A, El Bougrini J, Chelbi-Alix MK, Blondel D. The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1. Journal of virology. 2007; 81(8):4255–63. https://doi.org/10.1128/JVI.01930-06 PMID: 17287281

15. Wiltzer L, Larrous F, Oksayan S, Ito N, Marsh GA, Wang LF, et al. Conservation of a unique mechanism of immune evasion across the Lyssavirus genus. Journal of virology. 2012; 86(18):10194–9. https://doi.org/10.1128/JVI.01249-12 PMID: 22740405

16. Ulane CM, Rodriguez JJ, Parisien JP, Horvath CM. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. Journal of virology. 2003; 77(11):6385–93. https://doi.org/10.1128/jvi.77.11.6385-6393.2003 PMID: 12743296

17. Palosaari H, Parisien JP, Rodriguez JJ, Ulane CM, Horvath CM. STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. Journal of virology. 2003; 77 (13):7635–44. https://doi.org/10.1128/jvi.77.13.7635-7644.2003 PMID: 12805463

18. Caignard G, Lucas-Hourani M, Dhondt KP, Labernardiere JL, Petit T, Jacob Y, et al. The V protein of Tioman virus is incapable of blocking type I interferon signaling in human cells. PloS one. 2013; 8(1): e53881. https://doi.org/10.1371/journal.pone.0053881 PMID: 23342031

19. Reitsma JM, Sato H, Nevels M, Terhune SS, Paulus C. Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus. Journal of virology. 2013; 87(19):10763–76. https://doi.org/10.1128/JVI.01197-13 PMID: 23903834

20. Yang L, Wang R, Ma Z, Xiao Y, Nan Y, Wang Y, et al. Porcine Reproductive and Respiratory Syndrome Virus Antagonizes JAK/STAT3 Signaling via nsp5, Which Induces STAT3 Degradation. Journal of virology. 2017; 91(3):e02087–16. https://doi.org/10.1128/JVI.02087-16 PMID: 27881658

21. Lundquist A, Barre B, Bienvenu F, Hermann J, Avril S, Coqueret O. Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition. Blood. 2003; 101(10):4070–7. https://doi.org/10.1182/blood-2002-07-1994 PMID: 12531804

22. Lieu KG, Brice A, Wiltzer L, Hirst B, Jans DA, Blondel D, et al. The rabies virus interferon antagonist P protein interacts with activated STAT3 and inhibits Gp130 receptor signaling. Journal of virology. 2013; 87(14):8261–5. https://doi.org/10.1128/JVI.00989-13 PMID: 23698294

23. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical journal. 2003; 374(Pt 1):1–20. https://doi.org/10.1042/BJ20030407 PMID: 12773095

24. Rodriguez JJ, Wang LF, Horvath CM. Hendra virus V protein inhibits interferon signaling by preventing STAT1 and STAT2 nuclear accumulation. Journal of virology. 2003; 77(21):11842–5. https://doi.org/10.1128/jvi.77.21.11842-11845.2003 PMID: 14557668

25. Kuchipudi SV. The Complex Role of STAT3 in Viral Infections. J Immunol Res. 2015; 2015:272359. https://doi.org/10.1155/2015/272359 PMID: 26199948

26. Roca Suarez AA, Van Renne N, Baumert TF, Lupberger J. Viral manipulation of STAT3: Evade, exploit, and injure. PLoS pathogens. 2018; 14(3):e1006839. https://doi.org/10.1371/journal.ppat.1006839 PMID: 29543893

27. Ren C, Cheng X, Lu B, Yang G. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. European Journal of Cancer. 2013; 49(18):3889–99. https://doi.org/10.1016/j.ejca.2013.07.140 PMID: 23953057

28. Liu YP, Tan YN, Wang ZL, Zeng L, Lu ZX, Li LL, et al. Phosphorylation and nuclear translocation of STAT3 regulated by the Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. International journal of molecular medicine. 2008; 21(2):153–62. PMID: 18204781

29. Xu Y, Shi Y, Yuan Q, Liu X, Yan B, Chen L, et al. Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. Journal of experimental & clinical cancer research: CR. 2013; 32(1):90.

30. Muromoto R, Okabe K, Fujimuro M, Sugiyama K, Yokosawa H, Seya T, et al. Physical and functional interactions between STAT3 and Kaposi's sarcoma-associated herpesvirus-encoded LANA. FEBS letters. 2006; 580(1):93–8. https://doi.org/10.1016/j.febslet.2005.11.057 PMID: 16364321

31. Tu Z, Xu M, Zhang J, Feng Y, Hao Z, Tu C, et al. Pentagalloylglucose Inhibits the Replication of Rabies Virus via Mediation of the miR-455:SOCS3:STAT3:IL-6 Pathway. Journal of virology. 2019; 93(18): e00539–19. https://doi.org/10.1128/JVI.00539-19 PMID: 31243136

32. Delgoffe GM, Vignali DA. STAT heterodimers in immunity: A mixed message or a unique signal? Jak-stat. 2013; 2(1):e23060. https://doi.org/10.4161/jkst.23060 PMID: 24058793

33. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature reviews Immunology. 2005; 5(5):375–86. https://doi.org/10.1038/nri1604 PMID: 15864272

34. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012; 13(3):290–9. https://doi.org/10.1038/ni.2227 PMID: 22306691

35. Novak U, Mui A, Miyajima A, Paradiso L. Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor. The Journal of biological chemistry. 1996; 271(31):18350–4. https://doi.org/10.1074/jbc.271.31.18350 PMID: 8702476

36. Shimizu K, Ito N, Sugiyama M, Minamoto N. Sensitivity of rabies virus to type I interferon is determined by the phosphoprotein gene. Microbiology and immunology. 2006; 50(12):975–8. https://doi.org/10.1111/j.1348-0421.2006.tb03875.x PMID: 17179666

37. Pasdeloup D, Poisson N, Raux H, Gaudin Y, Ruigrok RW, Blondel D. Nucleocytoplasmic shuttling of the rabies virus P protein requires a nuclear localization signal and a CRM1-dependent nuclear export signal. Virology. 2005; 334(2):284–93. https://doi.org/10.1016/j.virol.2005.02.005 PMID: 15780878

38. Shimizu K, Ito N, Mita T, Yamada K, Hosokawa-Muto J, Sugiyama M, et al. Involvement of nucleoprotein, phosphoprotein, and matrix protein genes of rabies virus in virulence for adult mice. Virus Res. 2007; 123(2):154–60. https://doi.org/10.1016/j.virusres.2006.08.011 PMID: 17010466

39. Lin J, Buettner R, Yuan YC, Yip R, Horne D, Jove R, et al. Molecular dynamics simulations of the conformational changes in signal transducers and activators of transcription, Stat1 and Stat3. J Mol Graph Model. 2009; 28(4):347–56. https://doi.org/10.1016/j.jmgm.2009.08.013 PMID: 19781967

40. Kubota T, Yokosawa N, Yokota S, Fujii N. C terminal CYS-RICH region of mumps virus structural V protein correlates with block of interferon alpha and gamma signal transduction pathway through decrease of STAT 1-alpha. Biochemical and biophysical research communications. 2001; 283(1):255–9. https://doi.org/10.1006/bbrc.2001.4764 PMID: 11322797

41. Kok SH, Hong CY, Kuo MY, Wang CC, Hou KL, Lin YT, et al. Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. Arthritis Rheum. 2009; 60(5):1451–62. https://doi.org/10.1002/art.24452 PMID: 19404962

42. Sadowski HB, Shuai K, Darnell JE Jr., Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 1993; 261:1739–44. https://doi.org/10.1126/science.8397445 PMID: 8397445

43. Yang E, Lerner L, Besser D, Darnell JE Jr. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. The Journal of biological chemistry. 2003; 278(18):15794–9. https://doi.org/10.1074/jbc.M213073200 PMID: 12600988

44. Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. The EMBO journal. 1990; 9(13):4477–84. PMID: 2176154

45. Gatto L, Berlato C, Poli V, Tininini S, Kinjyo I, Yoshimura A, et al. Analysis of SOCS-3 promoter responses to interferon gamma. The Journal of biological chemistry. 2004; 279(14):13746–54. https://doi.org/10.1074/jbc.M308999200 PMID: 14742442

46. Auernhammer CJ, Bousquet C, Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:6964–9. https://doi.org/10.1073/pnas.96.12.6964 PMID: 10359822

47. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BRG, et al. Regulation of c–myc expression by IFN–γ through Stat1-dependent and -independent pathways. The EMBO journal. 2000; 19(2):263–72. https://doi.org/10.1093/emboj/19.2.263 PMID: 10637230

48. Kramer OH, Heinzel T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Molecular and cellular endocrinology. 2010; 315(1–2):40–8. https://doi.org/10.1016/j.mce.2009.10.007 PMID: 19879327

49. Davis BM, Rall GF, Schnell MJ. Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). Annu Rev Virol. 2015; 2(1):451–71. https://doi.org/10.1146/annurev-virology-100114-055157 PMID: 26958924

50. Yang CH, Murti A, Pfeffer LM. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(10):5568–72. https://doi.org/10.1073/pnas.95.10.5568 PMID: 9576923

51. Larrea E, Aldabe R, Gonzalez I, Segura V, Sarobe P, Echeverria I, et al. Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells. Journal of virology. 2009; 83(7):3298–311. https://doi.org/10.1128/JVI.02167-08 PMID: 19158240

52. Mahony R, Gargan S, Roberts KL, Bourke N, Keating SE, Bowie AG, et al. A novel anti-viral role for STAT3 in IFN-alpha signalling responses. Cell Mol Life Sci. 2017; 74(9):1755–64. https://doi.org/10.1007/s00018-016-2435-3 PMID: 27988795

53. Pfeffer SR, Fan M, Du Z, Yang CH, Pfeffer LM. Unphosphorylated STAT3 regulates the antiprolifera-tive, antiviral, and gene-inducing actions of type I interferons. Biochemical and biophysical research communications. 2017; 490(3):739–45. https://doi.org/10.1016/j.bbrc.2017.06.111 PMID: 28642132

54. Hsia HC, Stopford CM, Zhang Z, Damania B, Baldwin AS. Signal transducer and activator of transcrip-tion 3 (Stat3) regulates host defense and protects mice against herpes simplex virus-1 (HSV-1) infec-tion. Journal of leukocyte biology. 2017; 101(4):1053–64. https://doi.org/10.1189/jlb.4A1016-199RR PMID: 27965384

55. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. The Journal of biological chemistry. 2006; 281(20):14111–8. https://doi.org/10.1074/jbc.M511797200 PMID: 16571725

56. Wang WB, Levy DE, Lee CK. STAT3 negatively regulates type I IFN-mediated antiviral response. Jour-nal of immunology (Baltimore, Md: 1950). 2011; 187(5):2578–85.

57. Tsai MH, Pai LM, Lee CK. Fine-Tuning of Type I Interferon Response by STAT3. Front Immunol. 2019; 10:1448. https://doi.org/10.3389/fimmu.2019.01448 PMID: 31293595

58. Lu L, Zhu F, Zhang M, Li Y, Drennan AC, Kimpara S, et al. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115(3):E498–E505. https://doi.org/10.1073/pnas.1715118115 PMID: 29295936

59. Tsai MH, Lee CK. STAT3 Cooperates With Phospholipid Scramblase 2 to Suppress Type I Interferon Response. Front Immunol. 2018; 9:1886. https://doi.org/10.3389/fimmu.2018.01886 PMID: 30158934

60. Yajima T, Yasukawa H, Jeon ES, Xiong D, Dorner A, Iwatate M, et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation. 2006; 114(22):2364–73. https://doi.org/10.1161/CIRCULATIONAHA.106.642454 PMID: 17101849

61. Zhu H, Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochemical and biophysical research communications. 2004; 324(2):518–28. https://doi.org/10.1016/j.bbrc.2004.09.081 PMID: 15474458

62. Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Molecular and cellular biology. 2001; 21(5):1621–32. https://doi.org/10.1128/MCB.21.5.1621-1632.2001 PMID: 11238899

63. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the domi-nant mediator of the anti-inflammatory effects of IL-10 in human macrophages. Journal of immunology (Baltimore, Md: 1950). 2004; 172(1):567–76.

64. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. European journal of immunology. 1989; 19(4):689–94. https://doi.org/10.1002/eji.1830190418 PMID: 2543584

65. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(1):11–9.

66. Johnson DE O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018; 15(4):234–48. https://doi.org/10.1038/nrclinonc.2018.8 PMID: 29405201

67. Yang R, Rincon M. Mitochondrial Stat3, the Need for Design Thinking. International Journal of Biological Sciences. 2016; 12(5):532–44. https://doi.org/10.7150/ijbs.15153 PMID: 27019635

68. Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, Minoux H, et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell. 2012; 48(5):667–80. https://doi.org/10.1016/j.molcel.2012.09.013 PMID: 23084476

69. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. The Journal of cell biology. 2006; 172(2):245–57. https://doi.org/10.1083/jcb.200503021 PMID: 16401721

70. Verma NK, Dourlat J, Davies AM, Long A, Liu WQ, Garbay C, et al. STAT3-stathmin interactions control microtubule dynamics in migrating T-cells. The Journal of biological chemistry. 2009; 284(18):12349–62. https://doi.org/10.1074/jbc.M807761200 PMID: 19251695

71. Baloul L, Lafon M. Apoptosis and rabies virus neuroinvasion. Biochimie. 2003; 85(8):777–88. https://doi.org/10.1016/s0300-9084(03)00137-8 PMID: 14585545

72. Miyamoto K, Matsumoto S. Comparative studies between pathogenesis of street and fixed rabies infec-tion. The Journal of experimental medicine. 1967; 125(3):447–56. https://doi.org/10.1084/jem.125.3.447 PMID: 6016898

73. Iwasaki Y, Liu D, Yamamoto T, Konno H. On the replication and spread of rabies virus in the human central nervous system. Journal of Neuropathology and Experimental Neurology. 1985; 44(2):185–95. https://doi.org/10.1097/00005072-198503000-00007 PMID: 3882892

74. Tobiume M, Sato Y, Katano H, Nakajima N, Tanaka K, Noguchi A, et al. Rabies virus dissemination in neural tissues of autopsy cases due to rabies imported into Japan from the Philippines: immunohistochemistry. Pathol Int. 2009; 59(8):555–66. https://doi.org/10.1111/j.1440-1827.2009.02406.x PMID: 19627539

75. Oksayan S, Ito N, Moseley G, Blondel D. Subcellular trafficking in rhabdovirus infection and immune evasion: a novel target for therapeutics. Infectious disorders drug targets. 2012; 12(1):38–58. https://doi.org/10.2174/187152612798994966 PMID: 22034934

76. Bach M, Grigat S, Pawlik B, Fork C, Utermohlen O, Pal S, et al. Fast set-up of doxycycline-inducible protein expression in human cell lines with a single plasmid based on Epstein-Barr virus replication and the simple tetracycline repressor. The FEBS journal. 2007; 274(3):783–90. https://doi.org/10.1111/j.1742-4658.2006.05623.x PMID: 17288558

77. Bussereau F, Vincent J, Coudrier D, Sureau P. Monoclonal Antibodies to Mokola Virus for Identification of Rabies and Rabies-Related Viruses. J Clin Microbiol. 1988; 26(12):2489–94. https://doi.org/10.1128/JCM.26.12.2489-2494.1988 PMID: 3068246